Jeanne Mendell

Summary

Publications

  1. doi request reprint The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults
    Jeanne Mendell
    Daiichi Sankyo Pharma Development, 399 Thornall Street, Edison, NJ, 08837, USA
    Clin Drug Investig 35:447-53. 2015
  2. pmc Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor
    Jeanne Mendell
    Daiichi Sankyo Pharma Development, 399 Thornall Street, Edison, NJ, 08837, USA
    Am J Cardiovasc Drugs 13:331-42. 2013
  3. doi request reprint The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor
    Jeanne Mendell
    Daiichi Sankyo Pharma Development, Edison, NJ 08837, USA
    J Cardiovasc Pharmacol 62:212-21. 2013
  4. pmc A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin
    Jeanne Mendell
    Daiichi Sankyo Pharma Development, Edison, NJ 08837, USA
    Br J Clin Pharmacol 75:966-78. 2013
  5. doi request reprint Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination
    Jeanne Mendell
    Department of Translational Medicine and Clinical Pharmacology, Daiichi Sankyo Pharma Development, Edison, NJ 08837, USA
    J Cardiovasc Pharmacol 60:335-41. 2012
  6. doi request reprint Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery
    Shashank Rohatagi
    Daiichi Sankyo India Pharma Private Ltd, Mumbai, India
    Thromb Haemost 108:887-95. 2012
  7. doi request reprint Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers
    Jeanne Mendell
    MPH, Daiichi Sankyo Pharma Development, 399 Thornall St, Edison, NJ 08837, USA
    J Clin Pharmacol 51:687-94. 2011
  8. doi request reprint Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects
    Hamim Zahir
    Daiichi Sankyo Pharma Development, 399 Thornall Street, Edison, NJ 08837, USA
    Thromb Haemost 108:166-75. 2012
  9. doi request reprint Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans
    Mohinder S Bathala
    Daiichi Sankyo Pharma Development, Edison, New Jersey, USA
    Drug Metab Dispos 40:2250-5. 2012
  10. doi request reprint Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation
    Daniel E Salazar
    Daiichi Sankyo Pharma Development, 399 Thornall St, Edison, NJ 08837, USA
    Thromb Haemost 107:925-36. 2012

Collaborators

  • Abdel Baset Halim
  • Robert P Giugliano
  • Shashank Rohatagi
  • Hamim Zahir
  • Daniel E Salazar
  • Mohinder S Bathala
  • Ling He
  • George Zhang
  • Hiroshi Masumoto
  • Nobuko Matsushima
  • Simon Zhou
  • Chris Lowrie
  • Masaya Tachibana
  • Indravadan Patel
  • Elliott M Antman
  • Satoshi Kunitada
  • Tomas S Bocanegra
  • Timothy J Carrothers
  • Valerie Worland
  • Saeheum Song
  • Helen Kastrissios
  • Minggao Shi
  • Frank Lee
  • Toshihiro Oguma
  • Bruce Dornseif
  • Michelle Green

Detail Information

Publications12

  1. doi request reprint The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults
    Jeanne Mendell
    Daiichi Sankyo Pharma Development, 399 Thornall Street, Edison, NJ, 08837, USA
    Clin Drug Investig 35:447-53. 2015
    ..The effect of rifampin-induced induction of P-gp and CYP3A4/5 on transport and metabolism of edoxaban through the CYP3A4/5 pathway was investigated in a single-dose edoxaban study...
  2. pmc Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor
    Jeanne Mendell
    Daiichi Sankyo Pharma Development, 399 Thornall Street, Edison, NJ, 08837, USA
    Am J Cardiovasc Drugs 13:331-42. 2013
    ..P-glycoprotein (P-gp), an efflux transporter, modulates absorption and excretion of xenobiotics. Edoxaban is a P-gp substrate, and several cardiovascular (CV) drugs have the potential to inhibit P-gp and increase drug exposure...
  3. doi request reprint The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor
    Jeanne Mendell
    Daiichi Sankyo Pharma Development, Edison, NJ 08837, USA
    J Cardiovasc Pharmacol 62:212-21. 2013
    ..Inhibition of platelet aggregation by high-dose ASA, low-dose ASA, or naproxen was not affected by edoxaban. Concomitant administration of edoxaban and ASA or naproxen was well tolerated...
  4. pmc A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin
    Jeanne Mendell
    Daiichi Sankyo Pharma Development, Edison, NJ 08837, USA
    Br J Clin Pharmacol 75:966-78. 2013
    ..To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of edoxaban, an oral direct factor Xa inhibitor, in healthy subjects switching from warfarin...
  5. doi request reprint Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination
    Jeanne Mendell
    Department of Translational Medicine and Clinical Pharmacology, Daiichi Sankyo Pharma Development, Edison, NJ 08837, USA
    J Cardiovasc Pharmacol 60:335-41. 2012
    ..Edoxaban PD were consistent with PK. Both drugs were well tolerated alone or in combination. No clinically significant changes in PK, PD, or renal elimination were observed with concomitant administration of edoxaban and digoxin...
  6. doi request reprint Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery
    Shashank Rohatagi
    Daiichi Sankyo India Pharma Private Ltd, Mumbai, India
    Thromb Haemost 108:887-95. 2012
    ..These analyses suggest that edoxaban has a predictable anticoagulant effect in this patient population leading to dose-proportional reduction in incidence of VTE with low incidence of bleeding...
  7. doi request reprint Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers
    Jeanne Mendell
    MPH, Daiichi Sankyo Pharma Development, 399 Thornall St, Edison, NJ 08837, USA
    J Clin Pharmacol 51:687-94. 2011
    ..Both Japanese and Caucasian volunteers demonstrated a modest but clinically insignificant food effect. It was concluded that edoxaban can be administered without regard to food...
  8. doi request reprint Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects
    Hamim Zahir
    Daiichi Sankyo Pharma Development, 399 Thornall Street, Edison, NJ 08837, USA
    Thromb Haemost 108:166-75. 2012
    ..There were no serious adverse events during the study. It is concluded that a 60-mg dose of edoxaban can be safely administered 12 h following enoxaparin 1 mg/kg...
  9. doi request reprint Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans
    Mohinder S Bathala
    Daiichi Sankyo Pharma Development, Edison, New Jersey, USA
    Drug Metab Dispos 40:2250-5. 2012
    ..Edoxaban is eliminated through multiple pathways, but each accounts for only a small amount of overall elimination...
  10. doi request reprint Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation
    Daniel E Salazar
    Daiichi Sankyo Pharma Development, 399 Thornall St, Edison, NJ 08837, USA
    Thromb Haemost 107:925-36. 2012
    ....
  11. doi request reprint Ex vivo reversal of the anticoagulant effects of edoxaban
    Abdel Baset Halim
    Daiichi Sankyo Pharma Development, 399 Thornall Street, Edison, NJ 08837, Edison, NJ, USA Electronic address
    Thromb Res 134:909-13. 2014
    ....
  12. doi request reprint An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics
    Jeanne Mendell
    Daiichi Sankyo Pharma Development, Edison, NJ, USA
    J Clin Pharmacol 55:1395-405. 2015
    ..However, because of the potential for underlying coagulopathy, edoxaban is not recommended for use in patients with moderate or severe hepatic impairment. No dose reduction is recommended for patients with mild hepatic impairment. ..